3/28
04:43 pm
cnta
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 [Yahoo! Finance]
Medium
Report
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 [Yahoo! Finance]
3/28
04:28 pm
cnta
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Medium
Report
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
3/14
10:30 am
cnta
D3 Bio Appoints Dr. Antoine Yver as Independent Board Member
Low
Report
D3 Bio Appoints Dr. Antoine Yver as Independent Board Member
3/12
01:22 pm
cnta
Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m [Yahoo! Finance]
Low
Report
Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m [Yahoo! Finance]
2/26
07:07 am
cnta
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz [Yahoo! Finance]
Low
Report
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz [Yahoo! Finance]
2/22
08:09 am
cnta
Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference [Yahoo! Finance]
2/22
08:00 am
cnta
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
Low
Report
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
2/9
07:15 am
cnta
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
High
Report
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
2/9
07:00 am
cnta
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
High
Report
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
1/22
08:00 am
cnta
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences